AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 87 filers reported holding AVADEL PHARMACEUTICALS PLC in Q2 2022. The put-call ratio across all filers is 0.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $226,085 | -32.9% | 21,950 | +7.3% | 0.00% | -33.3% |
| Q2 2023 | $337,016 | +162.8% | 20,450 | +46.1% | 0.00% | +200.0% |
| Q1 2023 | $128,240 | +14.4% | 14,000 | -10.5% | 0.00% | 0.0% |
| Q4 2022 | $112,054 | -100.0% | 15,650 | -83.3% | 0.00% | -66.7% |
| Q3 2022 | $235,235,000 | +317785.1% | 93,800 | +208.6% | 0.00% | +200.0% |
| Q2 2022 | $74,000 | -76.7% | 30,400 | -34.7% | 0.00% | -66.7% |
| Q1 2022 | $318,000 | +16.9% | 46,550 | +38.3% | 0.00% | 0.0% |
| Q4 2021 | $272,000 | +177.6% | 33,650 | +236.5% | 0.00% | +200.0% |
| Q3 2021 | $98,000 | +46.3% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $67,000 | -25.6% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $90,000 | +34.3% | 10,000 | -0.2% | 0.00% | 0.0% |
| Q4 2020 | $67,000 | -99.9% | 10,017 | +0.2% | 0.00% | 0.0% |
| Q3 2020 | $50,000,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,409,289 | $24,815,676 | 12.25% |
| Knoll Capital Management, LLC | 600,000 | $6,180,000 | 6.42% |
| Vivo Capital, LLC | 4,096,428 | $42,193,208 | 4.62% |
| GENDELL JEFFREY L | 5,615,350 | $57,838,105 | 3.29% |
| Tri Locum Partners LP | 983,602 | $10,131,101 | 3.24% |
| Samsara BioCapital, LLC | 967,527 | $9,965,528 | 3.05% |
| MPM BioImpact LLC | 664,224 | $6,841,507 | 1.83% |
| COWEN AND COMPANY, LLC | 2,338,302 | $24,084,510 | 1.68% |
| RTW INVESTMENTS, LP | 7,136,415 | $73,505,075 | 1.55% |
| TANG CAPITAL MANAGEMENT LLC | 1,000,000 | $10,300,000 | 1.45% |